Potential role of immunomodulators for treatment of phlebovirus infections of animals.
Rift Valley fever (RVFV) is a major phlebovirus-induced epizootic disease of domestic animals (primarily cattle and sheep) in Africa. No therapies for the disease are known. A related phlebovirus, Punta Toro virus (PTV), has been adapted to induce an RVFV-like disease in C57BL/6 mice. This PTV infection has been used as a model for RVFV because it is reasonably safe and does not require high-level biologic containment. The infection model has been used to study the potential role of immunomodulating substances as therapies. A spectrum of immunomodulators has been studied; those immunomodulators most capable of preventing death and other disease manifestations are ampligen, bropirimine, poly (ICLC), AM-3, P-136, and 7-thia-8-oxoguanosine. An immunologic parameter common to all these substances has been their ability to induce interferon. Timing studies have indicated that these active substances may be administered therapeutically as well as prophylactically to inhibit markedly the progress of the disease. Further work is needed in the development of these materials for use in treating viral infections in domestic animals. As a next step, studies need to be run to compare the immunologic profiles induced by each substance in domestic animals and in mice.
Sidwell
R W
RW
Institute for Antiviral Research, Utah State University, Logan 84322-5600.
Huffman
J H
JH
Smee
D F
DF
Gilbert
J
J
Gessaman
A
A
Pease
A
A
Warren
R P
RP
Huggins
J
J
Kende
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D010217:Phlebotomus Fever / Q000628:therapy / Q000662:veterinary*; D016856:Phlebovirus; D012295:Rift Valley Fever / Q000628:therapy*; D013047:Specific Pathogen-Free Organisms
D000276:Adjuvants, Immunologic